2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Poly‐aneuploid cancer cells promote evolvability, generating lethal cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cancer cells utilize the forces of natural selection to evolve evolvability allowing a constant supply of heritable variation that permits a cancer species to evolutionary track changing hazards and opportunities. Over time, the dynamic tumor ecosystem is exposed to extreme, catastrophic changes in the conditions of the tumor—natural (e.g., loss of blood supply) or imposed (therapeutic). While the nature of these catastrophes may be varied or unique, their common property may be to doom the current cancer phenotype unless it evolves rapidly. Poly‐aneuploid cancer cells (PACCs) may serve as efficient sources of heritable variation that allows cancer cells to evolve rapidly, speciate, evolutionarily track their environment, and most critically for patient outcome and survival, permit evolutionary rescue, therapy resistance, and metastasis. As a conditional evolutionary strategy, they permit the cancer cells to accelerate evolution under stress and slow down the generation of heritable variation when conditions are more favorable or when the cancer cells are closer to an evolutionary optimum. We hypothesize that they play a critical and outsized role in lethality by their increased capacity for invasion and motility, for enduring novel and stressful environments, and for generating heritable variation that can be dispensed to their 2N+ aneuploid progeny that make up the bulk of cancer cells within a tumor, providing population rescue in response to therapeutic stress. Targeting PACCs is essential to cancer therapy and patient cure—without the eradication of the resilient PACCs, cancer will recur in treated patients.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer

          Abiraterone treats metastatic castrate-resistant prostate cancer by inhibiting CYP17A, an enzyme for testosterone auto-production. With standard dosing, evolution of resistance with treatment failure (radiographic progression) occurs at a median of ~16.5 months. We hypothesize time to progression (TTP) could be increased by integrating evolutionary dynamics into therapy. We developed an evolutionary game theory model using Lotka–Volterra equations with three competing cancer “species”: androgen dependent, androgen producing, and androgen independent. Simulations with standard abiraterone dosing demonstrate strong selection for androgen-independent cells and rapid treatment failure. Adaptive therapy, using patient-specific tumor dynamics to inform on/off treatment cycles, suppresses proliferation of androgen-independent cells and lowers cumulative drug dose. In a pilot clinical trial, 10 of 11 patients maintained stable oscillations of tumor burdens; median TTP is at least 27 months with reduced cumulative drug use of 47% of standard dosing. The outcomes show significant improvement over published studies and a contemporaneous population.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Ecological novelty and the emergence of evolutionary traps.

            Human-induced rapid environmental change (HIREC; e.g., climate change or exotic species) has caused global species declines. Although behavioral plasticity has buffered some species against HIREC, maladaptive behavioral scenarios called 'evolutionary traps' are increasingly common, threatening the persistence of affected species. Here, we review examples of evolutionary traps to identify their anthropogenic causes, behavioral mechanisms, and evolutionary bases, and to better forecast forms of HIREC liable to trigger traps. We summarize a conceptual framework for explaining the susceptibility of animals to traps that integrates the cost-benefit approach of standard behavioral ecology with an evolutionary approach (reaction norms) to understanding cue-response systems (signal detection). Finally, we suggest that a significant revision of conceptual thinking in wildlife conservation and management is needed to effectively eliminate and mitigate evolutionary traps.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Genome-wide genetic analysis of polyploidy in yeast.

              Polyploidy, increased sets of chromosomes, occurs during development, cellular stress, disease and evolution. Despite its prevalence, little is known about the physiological alterations that accompany polyploidy. We previously described 'ploidy-specific lethality', where a gene deletion that is not lethal in haploid or diploid budding yeast causes lethality in triploids or tetraploids. Here we report a genome-wide screen to identify ploidy-specific lethal functions. Only 39 out of 3,740 mutations screened exhibited ploidy-specific lethality. Almost all of these mutations affect genomic stability by impairing homologous recombination, sister chromatid cohesion, or mitotic spindle function. We uncovered defects in wild-type tetraploids predicted by the screen, and identified mechanisms by which tetraploidization affects genomic stability. We show that tetraploids have a high incidence of syntelic/monopolar kinetochore attachments to the spindle pole. We suggest that this defect can be explained by mismatches in the ability to scale the size of the spindle pole body, spindle and kinetochores. Thus, geometric constraints may have profound effects on genome stability; the phenomenon described here may be relevant in a variety of biological contexts, including disease states such as cancer.
                Bookmark

                Author and article information

                Contributors
                samend2@jhmi.edu
                Journal
                Evol Appl
                Evol Appl
                10.1111/(ISSN)1752-4571
                EVA
                Evolutionary Applications
                John Wiley and Sons Inc. (Hoboken )
                1752-4571
                22 February 2020
                August 2020
                : 13
                : 7 , Evolution and Cancer ( doiID: 10.1111/eva.v13.7 )
                : 1626-1634
                Affiliations
                [ 1 ] The Brady Urological Institute Johns Hopkins School of Medicine Baltimore MD USA
                [ 2 ] Nordic Center for Earth Evolution University of Southern Denmark Odense Denmark
                [ 3 ] Translational Cancer Research Department of Laboratory Medicine Lund University Lund Sweden
                [ 4 ] Gerald R. Ford School of Public Policy University of Michigan Ann Arbor MI USA
                [ 5 ] Cancer Biology and Evolution Program and Department of Integrated Mathematical Oncology Moffitt Cancer Center Tampa FL USA
                Author notes
                [*] [* ] Correspondence

                Sarah R. Amend, The Brady Urological Institute, Johns Hopkins School of Medicine, 600 N Wolfe St., Marburg 105A, Baltimore, MD 21287 USA.

                Email: samend2@ 123456jhmi.edu

                Author information
                https://orcid.org/0000-0002-5606-1262
                Article
                EVA12929
                10.1111/eva.12929
                7484876
                32952609
                91c7ff07-baa5-46ee-8b2a-525b4f1cef7b
                © 2020 The Authors. Evolutionary Applications published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 30 October 2019
                : 15 January 2020
                : 16 January 2020
                Page count
                Figures: 2, Tables: 2, Pages: 9, Words: 7229
                Funding
                Funded by: Prostate Cancer Foundation , open-funder-registry 10.13039/100000892;
                Funded by: National Cancer Institute , open-funder-registry 10.13039/100000054;
                Award ID: CA093900
                Award ID: CA143055
                Award ID: CA163124
                Award ID: R01CA170595
                Award ID: U54CA143803
                Award ID: U54CA143970‐05
                Funded by: Patrick C. Walsh Prostate Cancer Research Fund
                Funded by: Swedish Royal Physiographic Society of Lund
                Funded by: Ronald Rose
                Funded by: MC Dean, Inc.
                Funded by: William and Marjorie Springer
                Funded by: Mary and Dave Stevens
                Funded by: Louis Dorfman
                Funded by: Jones Family Foundation
                Funded by: European Union's Horizon 2020 research and innovation program
                Award ID: 690817
                Funded by: Vetenskapsrådet , open-funder-registry 10.13039/501100004359;
                Award ID: 2015‐04693
                Funded by: Crafoordska Stiftelsen , open-funder-registry 10.13039/501100003173;
                Funded by: William and Carolyn Stutt Research Fund
                Categories
                Original Article
                Special Issue Original Articles
                Custom metadata
                2.0
                August 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.0 mode:remove_FC converted:11.09.2020

                Evolutionary Biology
                cancer ecology,cancer lethality,cancer speciation,evolvability,metastasis,pgcc,poly‐aneuploid cancer cell,polyploid giant cancer cell,therapeutic resistance,therapy resistance

                Comments

                Comment on this article